Evaluation of pharmacodynamic (PD) biomarkers in patients with metastatic pancreatic cancer treated with BL-8040, a novel CXCR4 antagonist.Manuel Hidalgo, Daniel D. Von Hoff, Salomon M. Stemmer et al.|Journal of Clinical Oncology|2018Cited by 6
A phase IIa trial to assess the safety and efficacy of BL-8040 and pembrolizumab in patients with metastatic pancreatic adenocarcinoma (PDAC)Manuel Hidalgo, Daniel D. Von Hoff, Ron Epelbaum et al.|Annals of Oncology|2018Cited by 4
Evaluation of pharmacodynamic (PD) biomarkers in patients with metastatic pancreatic cancer treated with BL-8040, a novel CXCR4 antagonist.Manuel Hidalgo, Daniel D. Von Hoff, Ron Epelbaum et al.|Journal of Clinical Oncology|2018Cited by 0